Browse the evidence

Healthier nutrient-based diet patterns do not cost significantly more per day than less healthy options, but cost more per 2000 kcal.

If you are trying to eat healthier, expect to pay more per calorie. This meta-analysis confirms that healthier nutrient-based diets cost about $1.56 more per 2000 kcal than less healthy options. However, the cost per day is not significantly different. This suggests that healthy foods are often more nutrient-dense but also more calorie-dense in terms of cost. To mitigate this, focus on affordable healthy staples like grains and dairy, which showed smaller or no price differences, and consider policy-level changes or subsidies to make healthy food more accessible.

SGLT2 inhibitors (specifically empagliflozin) reduce major adverse cardiovascular events (MACE) and cardiovascular death in patients with Type 2 Diabetes and established cardiovascular disease.

If you have Type 2 Diabetes and established cardiovascular disease, empagliflozin (10 or 25 mg daily) can significantly reduce your risk of major cardiovascular events and cardiovascular death. This benefit is observed even in patients with moderately reduced kidney function (eGFR > 30). The mechanism is likely related to hemodynamic changes rather than just glucose lowering.

Carriers of the BMI-increasing FTO rs9939609 minor allele exhibit a specific genetic predisposition to consume higher dietary protein, independent of total energy intake or BMI.

If you carry the FTO risk variant for obesity, you may have a biological tendency to prefer protein-rich foods. Instead of viewing this as a flaw, use it: structure your meals to be higher in protein. This aligns with your genetic appetite signals, potentially making it easier to manage satiety and body weight without strictly counting total calories.

Lifestyle factors (smoking, lipids, hypertension, diabetes, obesity, diet, inactivity, alcohol, psychosocial factors) account for over 90% of the risk for acute myocardial infarction and stroke.

Your risk of heart attack or stroke is overwhelmingly determined by your lifestyle, not your genes. Nine key factors—smoking, blood lipids, blood pressure, diabetes, obesity, diet, physical inactivity, alcohol, and psychosocial stress—account for over 90% of this risk. Addressing these factors can drastically reduce your likelihood of these events.

GLP-1 receptor agonists (GLP-1RA) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide cardiovascular and renal benefits in T2D patients, whereas sulphonyureas are associated with increased cardiovascular mortality.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about GLP-1RA or SGLT2i medications, as they protect your heart and kidneys. Avoid sulphonyureas if possible, as they may increase cardiovascular risk.

Excess body fat during childhood and adolescence causally increases the risk of developing Polycystic Ovary Syndrome (PCOS) in adulthood, independent of adult body size.

Maintaining healthy body composition during childhood and adolescence is critical for preventing PCOS later in life. Even if adult weight is normal, excess fat during youth leaves a lasting metabolic imprint (insulin resistance/low SHBG) that increases PCOS risk. Early lifestyle interventions are the most effective prevention strategy.

Adult obesity and overweight significantly increase the odds of PCOS, with adolescents showing even higher odds than adults for the same degree of adiposity.

Maintaining a healthy weight in adulthood reduces PCOS risk, but adolescent weight is even more critical. Adolescents with overweight or obesity face higher odds of developing PCOS than adults with the same conditions. Prioritize healthy weight management during teenage years.

Lifestyle interventions for obesity typically result in modest long-term weight loss (5-10%) and high rates of weight regain due to potent biological adaptations, specifically increased appetite and reduced energy expenditure.

If you lose weight through diet and exercise, expect your body to fight back with increased hunger and a slower metabolism. This is a normal biological response, not a failure of willpower. To maintain loss, you may need ongoing support or pharmacological intervention to counteract these specific hormonal signals.

Obesity results from a complex interaction between environmental factors (e.g., ultra-processed foods, reduced physical activity) and genetic susceptibility, rather than environmental factors alone.

Recognize that your genetics may predispose you to weight gain, but this does not mean you are powerless. Understanding this interaction can help you adopt more effective, personalized strategies for managing your weight, such as working with healthcare providers on targeted interventions.

Obesity significantly increases the risk of cardiovascular diseases (CVDs), including hypertension, coronary artery disease, heart failure, and arrhythmias, through mechanisms involving inflammation, endothelial dysfunction, and cardiac structural changes.

If you have obesity, you are at a significantly higher risk for heart disease, high blood pressure, and heart failure. This risk is driven by inflammation and structural changes in the heart. Weight loss through lifestyle changes is crucial for managing these risks. Regular screening for blood pressure, cholesterol, and heart function is recommended.

Obesity is a major risk factor for various cancers, including endometrial, ovarian, prostate, colorectal, pancreatic, liver, gallbladder, kidney, thyroid, and meningioma, as well as hematological malignancies like multiple myeloma and leukemia.

Maintaining a healthy weight reduces your risk of developing several types of cancer, including colorectal, kidney, and endometrial cancer. Weight management through lifestyle changes is a key preventive strategy.

Obesity is a significant risk factor for respiratory diseases, including obstructive sleep apnea (OSA), obesity hypoventilation syndrome (OHS), and asthma, primarily due to mechanical effects on lung volume and airway collapse.

If you have obesity, you are at higher risk for sleep apnea and breathing problems. Excess weight can narrow your airways and reduce lung capacity. Losing weight can help improve breathing and reduce the severity of conditions like asthma and sleep apnea.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and tirzepatide reduce body weight primarily by suppressing energy intake through activation of GLP-1 receptors in the central nervous system (CNS) and peripheral vagal afferent pathways, rather than by increasing energy expenditure.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, primarily by reducing appetite and food intake through brain and gut signaling. They are taken once weekly. While they achieve significant weight loss (15-20%+ in trials), real-world results vary, and about a third of users may not lose enough weight to be clinically effective. Common side effects like nausea are frequent but often manageable with dose titration. These drugs are not a magic bullet for everyone, especially those with type 2 diabetes or lower starting weights, and require medical supervision.

Structured endurance or resistance exercise training induces distinct, comprehensive molecular adaptations across multiple organ systems, serving as the mechanistic basis for health benefits.

This paper establishes that endurance and resistance exercises trigger different molecular pathways. To maximize health benefits, you should incorporate both types of exercise, as they affect different molecular transducers in your muscles, fat, and blood. The specific molecular details are still being mapped, but the structural commitment (12 weeks) is key to seeing these changes.

Semaglutide (1.0 mg/week) significantly reduces major kidney disease events, slows eGFR decline, and lowers MACE risk in patients with type 2 diabetes and chronic kidney disease.

If you have type 2 diabetes and kidney disease, semaglutide (1 mg weekly) is a proven treatment to protect your kidneys from failing and reduce your risk of heart events. It is taken as a weekly injection, starting at a low dose to minimize side effects, and works alongside your current blood pressure medications.

Tirzepatide (up to 15 mg/week) reduces the risk of worsening heart failure and cardiovascular death in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction and obesity, tirzepatide (up to 15 mg weekly) can help reduce your risk of heart failure worsening and cardiovascular death. It is taken as a weekly injection, escalated to the maximum tolerated dose.

GLP-1RAs confer cardiovascular protection by reducing the risk of major adverse cardiovascular events (MACE), including death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, particularly in patients with established cardiovascular disease and obesity.

If you have obesity and existing heart disease, GLP-1 receptor agonists like semaglutide can significantly reduce your risk of heart attack, stroke, and cardiovascular death. This benefit is independent of whether you have diabetes, making these medications a crucial part of cardiovascular risk management for obese patients.

Using multiple 24-hour recalls (averaging 2-3) significantly improves the correlation with true intake compared to a single recall, but still yields low attenuation factors for energy and protein.

If you must use self-report, do not rely on a single day. Use 2-3 days of recalls to improve accuracy, but understand that the correlation with true intake remains low (0.31 for energy). For precise absolute intake, use biomarkers.

Higher Body Mass Index (BMI) is a strong predictor of increased under-reporting of energy and protein intake in both FFQs and 24-hour recalls.

If you have a higher BMI, your self-reported food intake is likely to be significantly underestimated. Use calibration equations that include your BMI to get a more accurate estimate of your true intake.

Gastrointestinal adverse events (nausea, vomiting, diarrhea) associated with once-weekly semaglutide 2.4 mg are transient, mild-to-moderate, and contribute negligibly (<1 percentage point) to the total weight loss achieved.

If you are prescribed once-weekly semaglutide 2.4 mg, expect gastrointestinal side effects like nausea or diarrhea, especially when starting or increasing the dose. These symptoms are typically mild, temporary, and resolve on their own. Crucially, do not assume these side effects are necessary for the drug to work; the medication causes weight loss primarily by regulating appetite and satiety, not by making you sick. Most patients tolerate the medication well enough to stay on the full dose.

Increasing cardiorespiratory fitness (CRF) or physical activity (PA) consistently reduces all-cause and cardiovascular mortality risk, whereas intentional weight loss does not consistently reduce mortality risk and may increase it in healthy individuals.

Prioritize increasing your physical activity and cardiorespiratory fitness over focusing on weight loss. Regular exercise provides consistent mortality benefits that are independent of whether you lose weight. If you are overweight or obese, becoming 'fit' significantly lowers your health risks, often more effectively than trying to lose weight alone.

Visceral adipose tissue accumulation is a primary risk factor for cardiometabolic disease, whereas subcutaneous fat is metabolically neutral or healthy.

Not all fat is created equal. Visceral fat (around your organs) is dangerous and increases your risk of diabetes and heart disease. Subcutaneous fat (under your skin) is less harmful. Focus on reducing visceral fat through diet and exercise, as this has the biggest impact on your metabolic health.

A 10-year intensive lifestyle intervention (caloric restriction and increased physical activity) significantly delays the onset of moderate or severe physical disability and increases disability-free life expectancy in adults with type 2 diabetes, particularly in women and those without cardiovascular disease.

If you have type 2 diabetes, committing to a structured lifestyle program involving calorie-controlled eating and regular physical activity (aiming for ~175 minutes of moderate activity per week) can significantly delay the onset of physical disability. This benefit is particularly pronounced for women and those without existing heart disease. While it may not extend your total lifespan, it can add nearly a year to your life spent free from physical limitations, improving your quality of life in your later years.

GLP-1 receptor agonists (GLP-1RAs) reduce body weight primarily by suppressing food intake through central nervous system mechanisms, including hypothalamic and hindbrain signaling and vagal afferent stimulation.

GLP-1 medications like semaglutide and liraglutide help you lose weight by signaling your brain to feel full and eat less, rather than by burning more calories. This effect is driven by the drug acting on satiety centers in the brain and vagus nerve. While side effects like nausea are common initially, they often subside over time. Consistent use is required to maintain weight loss, as stopping the medication typically leads to weight regain.